



NOW[®] *Legionella*

Rapid identification of *Legionella pneumophila* serogroup 1

- NOW[®] *Legionella* detects a pathogen that is a leading cause of bacterial nosocomial and community-acquired pneumonias.
- NOW[®] *Legionella* provides physicians with immediate pathogen identification thereby reducing hospital costs and improving patient outcomes.

About *Legionella*

An estimated 25,000 to 100,000 cases of *Legionella* infection occur in the United States annually^{1,2}.

The majority of Legionnaires' Disease is caused by *Legionella pneumophila* serogroup 1 and is characterized as an acute febrile respiratory illness that can be fatal.¹

Legionnaires' Disease is not contagious, it is transmitted via water sources (vapor, aerosolized droplets).

Typical risk factors for Legionnaires' Disease:³

- Heavy cigarette smoking
- Chronic lung disease
- Middle age or over

NOW[®]

- Easy
- Rapid
- Accurate



Laboratory Diagnosis of *Legionella*

Traditional antigen detection methods include direct fluorescent antibody (DFA) and enzyme immunoassay (EIA). These methods are not widely accepted due to time requirements, while DFA is subjective and lacks reliability.

Rapid test – NOW® *Legionella* detects *Legionella pneumophila* serogroup 1 from a urine sample within 15 minutes with high sensitivity and specificity.




NOW® *Legionella* is a rapid test for the identification of *Legionella pneumophila* serogroup 1 using urine samples.

Performing the test is easy.

1. Place sample swab into device.



2. Add reagent to swab, then close device.



3. Read at 15 minutes.



Reading the test couldn't be easier.

One line = negative



Two lines = positive



Sensitivity of 95% & specificity of 95% compared to laboratory diagnosis.⁴

Ordering Information

852-000 Binax NOW *Legionella* Urinary Antigen Test (22 test kit)
852-010 Binax NOW *Legionella* Urinary Antigen Control Swab Pack



¹ Marston, B.J., H.B. Lipman, R.F. Breiman. Surveillance for Legionnaires' Disease: risk factors for morbidity and mortality. Arch. Intern. Med. 1994; 154:2417-2422.

² Horwitz, M.A., B.J. Marston, C.V. Broome, and R.F. Breiman. Prospects for vaccine development. Presented at the 4th International Symposium on *Legionella*, 1992. In: Barbaree, J.M., R.F. Breiman, and A.P. DuFour, eds. *Legionella: Current Status and Emerging Perspectives*. Washington, DC American Society for Microbiology, 1993.

³ www.legionella.org, accessed 4/9/04.

⁴ Binax *Legionella* product insert, 2003.